Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma

Cancer Research

Volumn 58, Issue 3, 1998, Pages 542-548

  Tsihlias, John ^a   Kapusta, Linda R ^a   DeBoer, Gerrit ^c   Morava Protzner, Izabella ^a   Zbieranowski, Ingrid ^b   Bhattacharya, Nandita ^a   Catzavelos, G Charles ^a   Klotz, Laurence H ^a   Slingerland, Joyce M ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SEMINAL VESICLE; TREATMENT FAILURE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CELL CYCLE PROTEINS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEINS;

EID: 0032005978     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1996. CA Cancer J. Clin., 46: 5-27, 1996.
2. National Cancer Institute of Canada. Canadian Cancer Statistics, p. 15. Toronto, Canada: National Cancer Institute of Canada, 1997.
3. Albertsen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F., and Fine, J. Long-term survival among men with conservatively treated localized prostate cancer. J. Am. Med. Assoc., 274: 626-631, 1995.
4. Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J., Adolfsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livne, P. M., and Warner, J. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med., 330: 242-248, 1994.
5. Goto, Y., Ohori, M., Arakawa, A., Kattan, M. W., Wheeler, T. M., and Scardino, P. T. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J. Urol., 156: 1059-1063, 1996.
6. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T., and Pearson, J. D. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J. Am. Med. Assoc., 277: 1445-1451, 1997.
7. Hunter, T., and Pines, J. Cyclins and cancer. II. Cyclin D and cdk inhibitors come of age. Cell, 79: 573-582, 1994.
8. Morgan, D. O. Principles of Cdk regulation. Nature (Lond.), 374: 131-134, 1995.
9. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
10. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
11. Norbury, C., and Nurse, P. Animal cell cycles and their control. Annu. Rev. Biochem., 61: 441-470, 1992.
12. Solomon, M. J. Activation of the various cyclin/cdc2 proteins. Curr. Opin. Cell Biol., 5: 180-186, 1993.
13. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
14. Murray, A. W. Creative blocks: cell cycle checkpoints and feedback controls. Nature (Lond.), 359: 599-604, 1992.
15. 1 control in mammalian cells. J. Cell Sci. Suppl., 18: 69-73, 1994.
16. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
17. Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
18. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumours. Cancer Res., 55: 1211-1214, 1995.
19. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
20. Ferrando, A. A., Balbin, M., Pendas, A. M., Vizoso, F., Velasco, G., and Lopez-Otin, C. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum. Genet., 97: 91-94, 1996.
21. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. Decreased levels of the cell cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
22. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Galluzzi, C., Lavin, P., Draetta, G., Pagano, M., and Loda, M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res., 57: 1259-1263, 1997.
23. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
24. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sugimachi, K., and Akiyoshi, T. p27 expression and gastric carcinoma. Nat. Med., 3: 593, 1997.
25. Schroder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K., and Pavone-Macaluso, M. The TNM classification of prostate cancer. Prostate Suppl., 4: 129-138, 1992.
26. 1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
27. Bacus, J. W., and Grace, L. J. Optical microscope system for standardized cell measurements and analysis. Appl. Optics, 26: 3280-3293, 1987.
28. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
29. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., B34: 187-220, 1972.
30. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. Am. Stat. Assoc. J., 53: 457-481, 1958.
31. Oesterling, J. E., Brendler, C. B., Epstein, J. I., Kimball, A. W., Jr., and Walsh, P. C. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J. Urol., 138: 92-98, 1987.
32. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S., and Stamey, T. A. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (Phila.), 66: 1225-1233, 1990.
33. Paulson, D. F. Impact of radical prostatectomy in the management of clinically localized disease. J. Urol. 152: 1826-1830, 1994.
34. Walsh, P. C., Partin, A. W., and Epstein, J. I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., 152: 1831-1836, 1994.
35. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P., and Barrett, D. M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., 152: 1850-1857, 1994.
36. Murphy, G. P., Mettlin, C., Menck, H., Winchester, D. P., and Davidson, A. M. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J. Urol., 152: 1817-1819, 1994.
37. Gerber, G. S., Thisted, R. A., Scardino, P. T., Frohmuller, H. G. W., Schroeder, F. H., Paulson, D. F., Middleton, A. W., Jr., Rukstalis, D. B., Smith, J. A., Jr., Schellhammer, P. F., Ohori, M., and Chodak, G. W. Results of radical prostatectomy in men with clinically localized prostate cancer. J. Am. Med. Assoc., 276: 615-619, 1996.
38. Ohori, M., Goad, J. R., Wheeler, T. M., Eastham, J. A., Thompson, T. C., and Scardino, P. T. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J. Urol., 152: 1843-1849, 1994.
39. Coetzee, L. J., Hars, V., and Paulson, D. F. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology, 47: 232-235, 1996.
40. Schild, S. E., Wong, W. W., Grado, G. L., Buskirk, S. J., Robinow, J. S., Frick, L. M., and Ferrigni, R. G. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin. Proc., 69: 613-619, 1994.
41. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
42. Hengst, L., and Reed, S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science (Washington DC), 271: 1861-1864, 1996.
43. kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol., in press, 1998.
44. Bostwick, D. G. Neoplasms of the prostate. In: D. G. Bostwick and J. N. Eble (eds.). Urologic Surgical Pathology, p. 343-421. St. Louis, MO: Mosby, 1997.
45. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
46. Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Polyak, K., Firpo, E., Tsai, L., Broudy, V., Perlmutter, R. M., Kaushansky, K., and Roberts, J. M. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and femal sterility in p27Kip1-deficient mice. Cell, 85: 733-744, 1996.
47. Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., and Koff, A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell, 85: 721-732, 1996.
48. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
49. Slingerland, J. M., Hengst, L., Pan, C-H., Alexander, D., Stampfer, M. R., and Reed, S. I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol. Cell. Biol., 14: 3683-3694, 1994.
50. Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., and Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
51. 1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science (Washington DC), 260: 536-539, 1993.
52. 1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ., 7: 1571-1578, 1996.
53. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M., Tetu, B., Emond, J., and Candas, B. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin. Invest. Med., 16: 499-509, 1993.
54. Van Poppel, H., De Ridder, D., Elgamal, A. A., Van de Voorde, W., Werbrouck, P., Ackaert, K., Oyen, R., Pittomvils, G., and Baert, L. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J. Urol., 154: 429-434, 1995.
55. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr., and Puras-Baez, A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol., 154: 424-428, 1995.
56. Goldenberg, S. L., Klotz, L. H., Srigley, J., Jewett, M. A., Mador, D., Fradet, Y., Barkin, J., Chin, J., Paquin, J., Bullock, M. J., and Laplante, S. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J. Urol., 156: 873-877, 1996.
57. Murphy, W. M., Soloway, M. S., and Barrows, G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer (Phila.), 68: 821-828, 1991.
58. Armas, O. A., Aprikian, A. G., Melamed, J., Cordon-Cardo, C., Cohen, D. W., Erlandson, R., Fair, W., R., and Reuter, V. E. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am. J. Surg. Pathol., 18: 979-991, 1994.
59. Civantos, F., Marcial, M. A., Banks, E. R., Ho, C., Speights, V. O., Drew, P. A., Murphy, W. M., and Soloway, M. Pathology of androgen deprivation therapy in prostate carcinoma: a comparative study of 173 patients. Cancer (Phila.), 75: 1634-1641, 1995.
60. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
61. Kyprianou, N., and Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122: 552-562, 1988.
62. English, H. F., Kyprianou, N., and Isaacs, J. T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate, 15: 233-250, 1989.
63. Kyprianou, N., and Isaacs, J. T. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol. Endocrinol., 3: 1515-1522, 1989.
64. Yang, R. M., Naitoh, J., Philipson, J., Wang, H., deKernion, J. B., Loda, M., and Reiter, R. E. Low levels of p27 protein expression predict poor disease-free survival in patients with pathological T2a-T3b adenocarcinoma of the prostate. J. Urol., in press, 1998.